How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Drug Safety Solutions and Pharmacovigilance Market
- By Solution Type: Adverse Event Reporting Systems, Signal Detection and Management, Risk Management Solutions, Regulatory Compliance Solutions, Case Processing Solutions
- By Service Type: Pharmacovigilance Outsourcing Services, Consulting Services, Data Management Services, Medical Review Services, Regulatory Submission Services
- By End User: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Regulatory Authorities, Healthcare Providers
- By Deployment Mode: On-Premise Solutions, Cloud-Based Solutions, Hybrid Solutions
- By Therapeutic Area: Oncology, Cardiovascular, Central Nervous System, Infectious Diseases, Respiratory
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Adverse Event Reporting Systems leads By Solution Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 300 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.183 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.191 →
Full report · locked preview
Everything inside the Drug Safety Solutions and Pharmacovigilance Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →IQVIA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Parexel International Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →PPD (Pharmaceutical Product Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ICON plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Covance Inc. (Labcorp Drug Development)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Syneos Health
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Charles River Laboratories
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Pharmacovigilance Services by Accenture
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Wipro Limited (Pharmacovigilance Services)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →TCS (Tata Consultancy Services)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cognizant Technology Solutions (Pharmacovigilance)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →SAS Institute (Pharmacovigilance Analytics)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →ArisGlobal
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Ennov
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Oracle Health Sciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Adverse Event Reporting Systems43.4
- Signal Detection and Management12.3
- Risk Management Solutions20.3
- Regulatory Compliance Solutions11.7
- Case Processing Solutions12.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- IQVIA22.8
- Parexel International Corporation21.3
- PPD (Pharmaceutical Product Development)12.1
- ICON plc3.6
- Covance Inc. (Labcorp Drug Development)8.0
- Syneos Health4.2
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.0
- Europe21.9
- Asia Pacific20.1
- Latin America13.3
- Middle East and Africa10.7
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| IQVIA | 80 | 86 | 75 | 83 | 88 | 92 | 84 |
| Parexel International Corporation | 82 | 89 | 88 | 78 | 69 | 68 | 79 |
| PPD (Pharmaceutical Product Development) | 88 | 63 | 69 | 86 | 68 | 74 | 75 |
| ICON plc | 81 | 68 | 70 | 81 | 69 | 58 | 71 |
| Covance Inc. (Labcorp Drug Development) | 56 | 73 | 53 | 54 | 61 | 74 | 62 |
| Syneos Health | 55 | 68 | 54 | 56 | 57 | 64 | 59 |
| Charles River Laboratories | 52 | 59 | 57 | 44 | 52 | 46 | 52 |
| Pharmacovigilance Services by Accenture | 39 | 38 | 52 | 39 | 45 | 44 | 43 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- IQVIA
- Parexel International Corporation
- PPD (Pharmaceutical Product Development)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| IQVIA | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Parexel International Corporation | ◐ | ◐ | ◐ | ◐ | ✓ | ◐ |
| PPD (Pharmaceutical Product Development) | ◐ | ◐ | ✓ | ✓ | − | ◐ |
| ICON plc | ✓ | ✓ | ◐ | ✓ | − | − |
| Covance Inc. (Labcorp Drug Development) | − | ◐ | − | ◐ | ◐ | ◐ |
| Syneos Health | ◐ | − | − | − | ◐ | ◐ |
| Charles River Laboratories | − | ◐ | − | − | ◐ | − |
| Pharmacovigilance Services by Accenture | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender2
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Solution Type in North America, then scale across Drug Safety Solutions and Pharmacovigilance Market — a $514M beachhead inside a $9.30B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Adverse Event Reporting Systems
Best fit — highest urgency & budget in Solution Type.
Signal Detection and Management
Strong fit — clear ROI and a fast path to value.
Risk Management Solutions
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Solution Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Service Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Solution Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Drug Safety Solutions and Pharmacovigilance Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Drug Safety Solutions and Pharmacovigilance Market is a high-growth opportunity — $1.81B by 2033, compounding at 10.4%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Solution Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Solution Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Service Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Drug Safety Solutions and Pharmacovigilance Market — a $1.49B market by 2033. Plan: grow share from 5.8% to 12.0%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 5.8% | 12.0% | Ahead |
| Revenue | $84M | $178M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.7% | 40.2% | On track |
| Customer retention | 89.2% | 96.9% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Solution Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Service Type capability
A defensible second engine — invest in Service Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Solution Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Service Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $19M capacity & capability investment
- Greenlight bolt-on M&A in Service Type
- Authorise North America expansion plan
- Fund R&D program for Solution Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeBehind
- Execution & talentBehind
Sales deck · value proposition
Win the Drug Safety Solutions and Pharmacovigilance Market conversation — a $5.49B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Solution Type
Goal Grow share in Solution Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Drug Safety Solutions and Pharmacovigilance Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Drug Safety Solutions and Pharmacovigilance Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Drug Safety and Pharmacovigilance Solution Market
Market size, share, segmentation and regional forecast.
$928M market · 2025 base year
View reportArbidol API Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportDrug Safety and Pharmacovigilance Software Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportDrug Safety and Pharmacovigilance Service Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportDrug Safety and Pharmacovigilance (PV) Software Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportDrug-Resistant Tuberculosis Treatment Market
Market size, share, segmentation and regional forecast.
$489M market · 2025 base year
View reportDrug Repurposing Market
Drug Repurposing Market is valued at USD 3.48 Billion in 2025 and is expected to reach USD 7.12…
$3.5B market · 2025 base year
View reportDrug Reprofiling Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportDrug Repositioning Service Market
Market size, share, segmentation and regional forecast.
$705M market · 2025 base year
View reportDrug Repositioning Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportDrug-releasing Pump Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportDrug Reference App Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy